抗体靶向人工 T 细胞和 NK 细胞衍生囊泡用于癌症免疫治疗
Antibody-Targeted Artificial T Cell and Natural Killer Cell Derived Vesicles for Cancer Immunotherapy.
FRONTIER PAPERS
Antibody-Targeted Artificial T Cell and Natural Killer Cell Derived Vesicles for Cancer Immunotherapy.
Targeting the NKG2D axis in head and neck squamous cell carcinoma: from molecular insights to clinical applications.
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression.
BND-22 是一种首次人体 ILT2 阻断抗体,在多种临床前模型中已显示出有效的抗肿瘤活性以及良好的安全性特征。BND-22 作为单药或与其他治疗药物联合用于癌症患者的临床评价正在进行中。
Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation.
Understanding the Interplay of CAR-NK Cells and Triple-Negative Breast Cancer: Insights from Computational Modeling.
Exploring the potential of CAR-NK cell therapy in the management of head and neck cancer (HNC): a narrative review.
CAR-NK 细胞通过将靶向细胞毒作用与更优的安全性特征相结合,为 HNSCC 提供了新的治疗途径。
共 6 条
MEMBER ACCOUNT
登录成功会直接打开下一页。